Codexis (CDXS) announced its first revenue-generating contract to manufacture siRNA material in its ECO Synthesis Innovation Lab. Codexis has ...

Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...

Codexis shares were 20% higher, at $3.07, after the company recorded its first revenue-generating contract to manufacture siRNA material in its ECO Synthesis Innovation Lab.

One explanation for phasing is that only one secondary siRNA is made per round. Possible routes for such synthesis are self-termination of RdRP activity, or more processive RdRP activity coupled ...

"The North American market is projected to grow at the highest CAGR during the Forecast" Oligonucleotide Synthesis Market Size by Product (Drugs (ASO, siRNA), Synthesized Oligo (Primer), Reagents ...

Our goal is ambitious: scaling our siRNA platform and accelerating recent technical progress in the synthesis of high-purity guide RNA for gene editing. We expect several key announcements this ...

In this study, the authors demonstrated that exosomes can serve as delivery vehicles to introduce AGO2-loaded siRNA into the cytoplasm of bacteria, and in turn down-regulated gene expression of ...

Codexis intends to sign its first development contract for its ECO Synthesis™ manufacturing services in the first half of 2025. Codexis expects to achieve pilot scale production of GLP-grade siRNA ...

The company is focusing on expanding its enzymatic synthesis technology for siRNA production. Codexis's performance in Q4 2024 was marked by challenges, as both revenue and EPS fell short of ...

Represents first project to enter the ECO Synthesis™ Innovation LabCore enzymes for ECO Synthesis™ technology have transitioned from research ...